Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
54°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Biora Therapeutics, Inc.
< Previous
1
2
Next >
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
May 07, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
May 06, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
April 30, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
April 08, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
April 04, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 03, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 01, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 26, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
March 18, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
March 11, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
February 26, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
February 08, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
January 22, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Provides Outlook for 2024
January 16, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
January 08, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
January 02, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
December 19, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
December 18, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
December 11, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
November 30, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
November 06, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Submits Updated IND Application for BT-600
October 30, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics to Submit Updated IND Application for BT-600
October 23, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
October 05, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
September 25, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
September 19, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 11, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
September 05, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 14, 2023
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.